Sou Hu Cai Jing·2025-08-14 13:51Group 1 - The core viewpoint of the articles highlights the financial performance and market position of Haohai Biological Technology Co., Ltd. in the medical device industry, indicating a decline in revenue and profit in the latest quarterly report [1][2] - As of August 14, Haohai's closing stock price was 54.63 yuan, with a PE ratio of 30.75 times, and a total market capitalization of 12.706 billion yuan [1] - The average PE ratio for the medical device industry is 55.76 times, with a median of 39.14 times, positioning Haohai at the 61st rank within the industry [1][2] Group 2 - The latest quarterly report for Q1 2025 shows Haohai achieved an operating revenue of 619 million yuan, a year-on-year decrease of 4.25%, and a net profit of 90.3121 million yuan, down 7.41% year-on-year, with a gross profit margin of 69.52% [1] - As of February 29, 2020, Haohai had 7,605 shareholders, an increase of 918 from the previous count, with an average holding value of 352,800 yuan and an average holding quantity of 27,600 shares [1]